Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
McKinsey
Chubb
Teva
Farmers Insurance
Cerilliant
Citi
Daiichi Sankyo
Chinese Patent Office

Generated: June 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206317

« Back to Dashboard

NDA 206317 describes TRIFERIC, which is a drug marketed by Rockwell Medical Inc and is included in two NDAs. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the TRIFERIC profile page.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ferric pyrophosphate citrate profile page.
Summary for 206317
Tradename:TRIFERIC
Applicant:Rockwell Medical Inc
Ingredient:ferric pyrophosphate citrate
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 206317
Ingredient-typeIron
Mechanism of ActionPhosphate Chelating Activity
Suppliers and Packaging for NDA: 206317
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TRIFERIC ferric pyrophosphate citrate SOLUTION;IV (INFUSION) 206317 NDA Rockwell Medical, Inc 57278-314 N 57278-314-01
TRIFERIC ferric pyrophosphate citrate SOLUTION;IV (INFUSION) 206317 NDA Rockwell Medical, Inc 57278-316 N 57278-316-03

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;IV (INFUSION)Strength27.2MG IRON/5ML (5.44MG IRON/ML)
Approval Date:Jan 23, 2015TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Apr 17, 2029Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:SOLUTION;IV (INFUSION)Strength272MG IRON/50ML (5.44MG IRON/ML)
Approval Date:Sep 4, 2015TE:RLD:Yes

Expired US Patents for NDA 206317

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate SOLUTION;IV (INFUSION) 206317-001 Jan 23, 2015 ➤ Sign Up ➤ Sign Up
Rockwell Medical Inc TRIFERIC ferric pyrophosphate citrate SOLUTION;IV (INFUSION) 206317-001 Jan 23, 2015 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
QuintilesIMS
AstraZeneca
McKinsey
UBS
Chinese Patent Office
US Department of Justice
Deloitte
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.